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Abstract
Aims/hypothesis We aimed to examine the effects of bariatric
surgery on microvascular complications in patients with type
2 diabetes using objective measures.
Methods Prospective case–control study of 70 obese surgical
patients with type 2 diabetes undergoing gastric bypass sur-
gery matched for age, sex and duration of diabetes to 25 med-
ical patients treated using international guidelines.
Microvascular complications were assessed before and 12–
18 months after intervention using urine albumin creatinine
ratio (ACR) measurements, two-field digital retinal images
and peripheral nerve conduction studies (in the surgical group
only).
Results Urine ACR decreased significantly in the surgical
group but increased in the medical group. There were no sig-
nificant differences between the surgical and medical groups
in the changes in retinopathy. There were no changes in the
nerve conduction variables in the surgical group.
Conclusions/interpretation In the short term, bariatric surgery
may be superior to medical care in the treatment of diabetic
nephropathy, but not retinopathy or neuropathy.
Keywords Bariatric surgery . Nephropathy . Neuropathy .
Obesity . Retinopathy
Abbreviations
ACR Albumin creatinine ratio
RYGB Roux-en-Y gastric bypass
SOS Swedish Obese Subjects study
Introduction
Bariatric surgery reduces weight and improves glycaemia in
the long term. The Swedish Obese Subjects (SOS) study used
registry data to show that the incidence of microvascular com-
plications in a subgroup of patients with type 2 diabetes
mellitus who underwent predominantly vertical banded
gastroplasty was lower than that in patients managed with
lifestyle interventions [1]. No study so far has used direct
clinical measures in a cohort of patients with type 2 diabetes
to assess changes in nephropathy, retinopathy and neuropathy
after Roux-en-Y gastric bypass (RYGB) surgery.
Methods
This prospective case–control study took place in a certified
centre of excellence for bariatric surgery. In all, 83 obese pa-
tients with type 2 diabetes undergoing RYGB surgery [2], the
‘surgical group’, were recruited between December 2010 and
October 2012. These patients were matched for age, sex and
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duration of diabetes to a ‘medical’ group of 25 patients who
did not undergo surgery but who were treated in the same
centre using the ADA and EASD guidelines [3].
BMI, HbA1c, BP, medication usage and microvascular
complications were assessed within the 6 months before and
at 12–18 months after the intervention. Nephropathy was
assessed using the mean of two early morning urine albumin
creatinine ratio (ACR) measurements. Albuminuria was de-
fined as an ACR value of ≥2.5 mg/mmol in men or ≥3.5
mg/mmol in women. Retinopathy was assessed with two-
field digital retinal images obtained from the English National
Screening Programme for Diabetic Retinopathy and were
graded by an independent ophthalmologist who was blinded
to the patient clinical information, using a five-stage disease
severity classification for diabetic retinopathy from the
International Clinical Diabetic Retinopathy and Diabetic
Macular Oedema Disease Severity Scales [4]. Improvement
or worsening was defined as a decrease or increase of at least
two steps in the same grading system, respectively. Peripheral
neuropathy was assessed through motor and sensory nerve
conduction studies, which were performed with standard tech-
niques of stimulation and recording using a Dantec electromy-
ography system (Copenhagen, Denmark). The motor nerves
tested were the common peroneal and tibial, and the sensory
nerves tested were the superficial radial and sural.
Descriptive statistics are expressed as mean±SEM or
median and interquartile range depending on normality
distribution or as percentages. Within-group comparisons
were made using paired sample Student’s t tests or the
Wilcoxon matched pairs test depending on normality dis-
tribution. The retinal data were categorical and analysed
using the χ2 test. Bonferroni correction for multiple com-
parisons was applied to the neurophysiological measure-
ments. The Pearson methodology was used to test corre-
lations between two variables at a time.
The trial protocols were approved by the West London 2
Research Ethics Committee (reference 10/H0711/69). All par-
ticipants gave written informed consent and the trials were
performed according to the principles of the Declaration of
Helsinki.
Results
In the surgical group, 70 patients completed the study as three
patients did not proceed to surgery because they were consid-
ered to be of too high surgical risk and 10 patients did not
return for all the follow-up testing. All 25 patients in the med-
ical group completed the study. There were no significant
baseline differences in sex, age and duration of diabetes be-
tween the surgical and medical groups.
BMI, systolic BP and HbA1c were significantly reduced in
the surgical, but not the medical groups at 1 year (Table 1).
Urine ACR decreased from 3.6 (1.7–9.3) mg/mmol to 1.7
(1.0–4.9) mg/mmol in the surgical group ( p=0.02), but
increased from 1.8 (1.2–5.3) mg/mmol to 3.6 (2.0–10.8)
mg/mmol in the medical group at 1 year ( p=0.03).
Subgroup analysis of the 30 surgical patients who had pre-
existing albuminuria at baseline showed a significant im-
provement from 8.5 (5.7–17.4) mg/mmol to 1.7 (1.0–6.1)
mg/mmol at 1 year ( p=0.009). Fifteen patients normalised
their ACR at 1 year. Of the 43 patients who had normal base-
line ACR, five developed albuminuria at 1 year post-surgery.
By contrast, ACR did not change significantly in the subgroup
of the 10 medical patients with pre-existing albuminuria
(p=0.43). All of these patients still had albuminuria post-in-
tervention, while out of the 14 patients without albuminuria
pre-intervention, five developed albuminuria post-interven-
tion. A χ2 test showed that there was a significant difference
between the surgical and medical group for the remission of
albuminuria (p=0.0009), but not for the new incidence of
albuminuria over the 1 year period ( p=0.10).
In the group of 56 surgical patients with complete retinal
photograph datasets, 17 had no diabetic retinopathy, 32 had
mild to moderate non-proliferative diabetic retinopathy, six
had severe non-proliferative diabetic retinopathy, and one
had proliferative diabetic retinopathy. At 1 year after surgery,
44 patients (78%) had no change, six (11%) had improved by
at least two steps and six (11%) deteriorated by at least two
steps in retinopathy severity grading. Of the six patients who
deteriorated, one required photocoagulation treatment post-
surgery. This patient had mild to moderate non-proliferative
diabetic retinopathy at baseline. The other five patients had no
retinopathy at baseline.
In the medical group, nine participants had no retinopathy,
nine had mild to moderate non-proliferative diabetic retinop-
athy, two had severe non-proliferative diabetic retinopathy
and one had proliferative diabetic retinopathy. After interven-
tion, 17 patients (81%) experienced no change; one patient
(5%) improved by at least two steps and three (14%) deterio-
rated by at least two steps in the retinopathy severity grading
scale. One patient required photocoagulation at follow-up.
There were no significant differences between the surgical
and medical groups in the rates of patients who deteriorated
or improved after intervention ( p=0.70 and p=0.67,
respectively).
In all, 54 participants in the surgical group underwent nerve
conduction studies and there were no clinically significant
changes in any of the nerve conduction variables at 1 year.
There were no significant correlations between changes in
ACR and change in HbA1c (r=−0.046, p=0.75), BMI (r=
−0.058, p=0.70), and systolic (r=−0.079, p=0.61) and dia-
stolic BP (r=0.042, p=0.79) in either group.
There were significant reductions in use of glucose-
lowering and BP-lowering medications in the surgical, but
not the medical group at 1 year follow-up (Tables 1 and 2).
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Discussion
In this prospective case–control study, we used direct and
objectivemarkers of nephropathy, retinopathy and neuropathy
and found that after 1 year, RYGB surgery may be superior to
medical treatments for nephropathy, but not for retinopathy. In
studies of intensive medical management, substantial and rap-
id reductions in blood glucose, similar to those that take place
after RYGB, were associated with paradoxical deterioration of
microvascular complications [5]. It was reassuring to observe
that the rates of patients experiencing worsening in retinopa-
thy in the RYGB group was not in excess to those observed in
patients receiving medical care based on international guide-
lines. The stability of neuropathy after 1 year was also
reassuring.
We, and others, have previously shown that albuminuria
improves early after bariatric surgery [6, 7] and this may trans-
late to better long-term renal outcomes, like those observed by
the SOS study [1]. Retinal and neuronal function may take
longer than 1 year after bariatric surgery to show clinically
meaningful changes. This is reminiscent of the very slow im-
provements in neuropathy after pancreatic or islet cell trans-
plantation in patients with type 1 diabetes mellitus [8]. The
mechanisms of improvement in albuminuria after bariatric
surgery remain unclear. We expect that despite the lack of
correlations, the reductions in blood pressure, HbA1c and
BMI contributed to the observed reductions in ACR.
Our study is limited by the small sample size, the non-
randomised design, short follow-up and lack of information on
peripheral neuropathy for the medically treated patients.
However, our findings could be used to power larger
randomised controlled trials that are necessary in this field. We
cannot exclude that some patients may have had an acute dete-
rioration in retinopathy that occurred before 12 months and then
partially recovered. We are, however, reassured that the surgical
patients whowere all followed at 3, 6 and 9months after surgery
did not complain of deteriorating vision. Moreover, the retinop-
athy findings at 1 year were also reassuring.
In summary, we have shown that compared with a group of
patients receiving best medical care, patients treated with bar-
iatric surgery experience substantial reductions in albumin-
uria. In the short term, bariatric surgery may be superior to
medical care in the treatment of diabetic nephropathy, but not
retinopathy or neuropathy.
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